Generation Bio Co (OQ:GBIO)

May 13, 2024 04:05 pm ET
Generation Bio Announces Recent Business Highlights and First Quarter 2024 Financial Results
ASGCT poster presentations described immune-quiet DNA (iqDNA) as partially single-stranded, produced by flexible, scalable, proprietary rapid enzymatic synthesis - Cash balance of $233.9 million still expected to fund operations into 2H 2027...
May 09, 2024 06:59 am ET
Generation Bio Announces the Presentation of Preclinical Data on iqDNA and ctLNP Platforms at the ASGCT 27th Annual Meeting
Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, today presented five posters on its immune-quiet DNA (iqDNA) and cell-targeted lipid nanoparticle (ctLNP)...
Apr 22, 2024 05:31 pm ET
Generation Bio Announces the Acceptance of Five Abstracts and an Invited Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, today announced that six abstracts highlighting preclinical data from its cell-targeted lipid nanoparticle...
Apr 02, 2024 06:59 am ET
Generation Bio to Present at the 23rd Annual Needham Virtual Healthcare Conference
Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will participate in a fireside...
Mar 06, 2024 04:20 pm ET
Generation Bio Reports Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, reported business highlights and fourth quarter and full year 2023 financial results. “Late last year we...
Feb 27, 2024 06:59 am ET
Generation Bio to Present at the 2024 TD Cowen Health Care Conference
Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will present at the 2024 TD Cowen...
Jan 03, 2024 04:05 pm ET
Generation Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will present at the 42nd Annual...
Nov 29, 2023 06:59 am ET
Generation Bio Announces Strategic Reorganization to Extend Cash Runway for Development of ctLNP and iqDNA Platforms
Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced a strategic reorganization to prioritize investment in the development of its cell-targeted lipid...
Nov 10, 2023 08:31 am ET
Thinking about buying stock in Generation Bio, Blink Charging, MDxHealth, Microvast Holdings, or Crexendo?
NEW YORK, Nov. 10, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GBIO, BLNK, MDXH, MVST, and CXDO.
Nov 09, 2023 04:15 pm ET
Generation Bio Reports Business Highlights and Third Quarter 2023 Financial Results
Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, reported business highlights and third quarter 2023 financial results. “The recent advances in our...
Oct 26, 2023 06:59 am ET
Generation Bio Announces Demonstration of Highly Selective T Cell Transduction In Vivo with Cell-Targeted LNP Platform
Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that it has reached two significant achievements through in vivo studies, including results...
Oct 18, 2023 06:59 am ET
Generation Bio Announces Breakthrough in its Non-Viral Genetic Medicine Platform with Novel “Immune-Quiet” DNA
Generation Bio Co. (Nasdaq:GBIO), a biotechnology company developing genetic medicines for people living with rare and prevalent diseases, today announced the development of a proprietary, novel DNA called immune-quiet DNA (iqDNA). iqDNA is an...
Sep 19, 2023 07:30 am ET
Generation Bio to Present at the Jefferies Cell & Genetic Medicine Summit
Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will participate in a fireside...
Aug 03, 2023 07:30 am ET
Generation Bio to Present at the Canaccord Genuity 43rd Annual Growth Conference 
Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Matt Norkunas, M.D., chief financial officer, will present at the 2023 Canaccord Healthcare...
Aug 02, 2023 04:15 pm ET
Generation Bio Reports Second Quarter 2023 Financial Results
Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, reported business highlights and second quarter 2023 financial results. “We continue to make encouraging...
May 31, 2023 07:30 am ET
Generation Bio to Present at the 2023 Jefferies Healthcare Conference
Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will present at the 2023...
May 10, 2023 04:15 pm ET
Generation Bio Reports Business Highlights and First Quarter 2023 Financial Results
Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, reported business highlights and first quarter 2023 financial results. “This year, we are focused on...
May 09, 2023 04:15 pm ET
Generation Bio to Present at the JMP Securities Life Sciences Conference
Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Matt Norkunas, M.D., chief financial officer, will present at the JMP Securities Life Sciences...
Apr 11, 2023 07:30 am ET
Generation Bio to Present at the 22nd Annual Needham Virtual Healthcare Conference 
Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will participate in a fireside...
Apr 05, 2023 07:30 am ET
Generation Bio Appoints Yalonda Howze, J.D. as Chief Legal Officer
Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Yalonda Howze, J.D. has been appointed chief legal officer and secretary. “We are delighted...
Mar 23, 2023 08:39 am ET
Thinking about buying stock in Advent Technologies, Generation Bio, Exela Technologies, Mullen Automotive, or Plug Power?
NEW YORK, March 23, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ADN, GBIO, XELA, MULN, and PLUG.
Mar 23, 2023 07:00 am ET
Moderna and Generation Bio Announce Strategic Collaboration to Develop Non-Viral Genetic Medicines
Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent...
Mar 21, 2023 04:15 pm ET
Generation Bio to Participate in the BMO Biopharma Spotlight Series: Novel Technologies for the Delivery of Genetic Medicines
Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that the company will participate in the Novel LNPs Targeting Diverse Tissues panel at the BMO...
Feb 27, 2023 07:30 am ET
Generation Bio to Present at the 43rd Annual Cowen Healthcare Conference 
Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will participate in the Gene...
Feb 23, 2023 04:28 pm ET
Generation Bio Outlines 2023 Strategic Priorities and Reports Fourth Quarter and Full Year 2022 Financial Results
Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, outlined its strategic priorities for 2023 and reported fourth quarter and full year 2022 financial results....
Jan 03, 2023 04:30 pm ET
Generation Bio to Present at the 41st Annual J.P. Morgan Healthcare Conference
Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that the company will present at the 41st Annual J.P. Morgan Healthcare Conference on January 10th...
Nov 03, 2022 04:15 pm ET
Generation Bio Reports Business Highlights and Third Quarter 2022 Financial Results
Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, reported business highlights and third quarter 2022 financial results. “Generation Bio’s mission is to...
Sep 22, 2022 07:30 am ET
Generation Bio to Present at the 2022 Jefferies Cell and Genetic Medicine Summit
Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that the company will participate in a fireside chat at the 2022 Jefferies Cell & Genetic Medicine...
Sep 20, 2022 07:30 am ET
Generation Bio Names Phillip Samayoa, Ph.D. Chief Strategy Officer
Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced the promotion of Phillip Samayoa, Ph.D., to chief strategy officer. Dr. Samayoa has led strategy,...
Aug 04, 2022 04:15 pm ET
Generation Bio Reports Business Highlights and Second Quarter 2022 Financial Results
Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, reported business highlights and second quarter 2022 financial results. “We are advancing our leading...
Aug 02, 2022 04:15 pm ET
Generation Bio to Present at the 2022 Wedbush PacGrow Healthcare Conference
Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that the company will participate in a panel at the virtual 2022 Wedbush PacGrow Healthcare...
Jul 18, 2022 07:30 am ET
Generation Bio Appoints Dannielle Appelhans to Its Board of Directors
Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced today that Dannielle Appelhans has been appointed to its Board of Directors. Dannielle Appelhans...
Jun 21, 2022 08:30 am ET
Generation Bio Announces Update to Its GMP Manufacturing Strategy
Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that it is updating its Good Manufacturing Process (GMP) manufacturing strategy to integrate...
Jun 02, 2022 07:30 am ET
Generation Bio to Present at the 2022 Jefferies Healthcare Conference
Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will participate in a fireside...
May 05, 2022 04:15 pm ET
Generation Bio Reports Business Highlights and First Quarter 2022 Financial Results
Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, reported business highlights and first quarter 2022 financial results. “We are making...
Apr 05, 2022 07:30 am ET
Generation Bio to Participate in 21st Annual Needham Virtual Healthcare Conference
Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will participate in a fireside...
Mar 02, 2022 07:30 am ET
Generation Bio to Participate in 42nd Annual Cowen Health Care Conference
Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will participate in the Gene...
Feb 24, 2022 04:20 pm ET
Generation Bio Outlines 2022 Strategic Priorities and Reports Fourth Quarter and Full Year 2021 Financial Results
Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, outlined its strategic priorities for 2022 and reported fourth quarter and full year 2021 financial results....
Feb 10, 2022 07:30 am ET
Generation Bio Promotes Antoinette Paone, M.S., MBA to Chief Operating Officer
Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced the promotion of Antoinette Paone to chief operating officer (COO). Ms. Paone has served as senior...
Jan 06, 2022 05:26 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Generation Bio Co. - GBIO
NEW YORK, Jan. 6, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Generation Bio Co. ("Generation" or the "Company") (NASDAQ: GBIO). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Jan 05, 2022 07:30 am ET
Generation Bio to Present at 40th Annual J.P. Morgan Healthcare Conference
Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced today that the company will present at the virtual 40th Annual J.P. Morgan Healthcare Conference...
Dec 28, 2021 07:37 pm ET
SHAREHOLDER ALERT: Robbins LLP Investigates Generation Bio Co. (GBIO) on Behalf of Shareholders
Shareholder rights law firm Robbins LLP is investigating Generation Bio Co. (NASDAQ: GBIO) to determine whether certain Generation Bio officers and directors violated the Securities Exchange Act of 1934 and breached fiduciary duties to shareholders. Generation Bio develops gene therapies for the treatment of rare and prevalent diseases.
Dec 19, 2021 09:37 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Generation Bio Co. - GBIO
Pomerantz LLP is investigating claims on behalf of investors of  Generation Bio Co. (“Generation” or the “Company”) (NASDAQ: GBIO). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The...
Dec 16, 2021 10:02 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Generation Bio Co. - GBIO
NEW YORK, Dec. 16, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Generation Bio Co. ("Generation" or the "Company") (NASDAQ: GBIO).  Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Dec 14, 2021 06:30 am ET
Generation Bio Provides Update on Preclinical Studies for Hemophilia A Program
Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, today provided an update on factor VIII expression from a series of mouse and companion non-human primate...
Nov 10, 2021 04:20 pm ET
Generation Bio Reports Business Highlights and Third Quarter 2021 Financial Results
Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, reported recent business highlights and third quarter 2021 financial results. “We are building a...
Oct 22, 2021 07:30 am ET
Generation Bio Presents Data Demonstrating First Lipid Nanoparticle to Achieve Uniform Retinal Transduction and Tolerability via Sub-Retinal Delivery of ceDNA and mRNA at the European Society of Gene
Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, today presented new preclinical data demonstrating widespread delivery of multiple nucleic acid cargos to...
Oct 21, 2021 04:05 pm ET
Generation Bio to Present at Jefferies Virtual Gene Therapy/Editing Summit
Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced today that Geoff McDonough, M.D., president and chief executive officer, will participate in a...
Oct 15, 2021 07:30 am ET
Generation Bio to Present at European Society of Gene and Cell Therapy 2021 Annual Virtual Congress
Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, today announced an oral presentation at the European Society of Gene and Cell Therapy (ESGCT) Annual Virtual...
Aug 11, 2021 04:20 pm ET
Generation Bio Reports Business Highlights and Second Quarter 2021 Financial Results
Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, reported recent business highlights and second quarter 2021 financial results. “This quarter we announced...
Aug 03, 2021 07:30 am ET
Generation Bio to Present at Wedbush PacGrow Healthcare Conference 2021
Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced today that Geoff McDonough, M.D., president and chief executive officer, will participate in a...
Jul 14, 2021 07:30 am ET
Generation Bio Announces Plan to Scale Next-Generation Rapid Enzymatic Manufacturing Process Across Portfolio and Provides Pipeline Update
Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced today that it plans to deploy next-generation rapid enzymatic synthesis (RES) for manufacturing of...
Jul 08, 2021 07:30 am ET
Generation Bio to Present at William Blair Biotech Focus Conference
Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, announced today that Geoff McDonough, M.D., president and chief executive officer, will present at the William Blair Biotech...
Jun 09, 2021 07:30 am ET
Generation Bio to Present at the JMP Securities Life Sciences Conference
Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, announced today that Geoff McDonough, M.D., president and chief executive officer, will present at the JMP Securities Life...
May 27, 2021 07:30 am ET
Generation Bio to Present at the Jefferies Virtual Healthcare Conference
Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, announced today that Geoff McDonough, M.D., president and chief executive officer, will present at the Jefferies Virtual...
May 12, 2021 04:20 pm ET
Generation Bio Presents Preclinical Data Demonstrating Broad Potential of Gene Therapy Platform at ASGCT and Reports First Quarter Financial Results
Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, today reported data from multiple digital presentations during the ongoing 24th American Society of Gene and Cell Therapy...
Apr 27, 2021 04:35 pm ET
Generation Bio to Present at American Society of Gene & Cell Therapy 2021 Virtual Annual Meeting
Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, today announced three digital presentations at the American Society of Gene & Cell Therapy (ASGCT) 2021 Virtual Annual...
Apr 08, 2021 07:30 am ET
Generation Bio to Present at 20th Annual Needham Virtual Healthcare Conference
Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, announced today that Geoff McDonough, M.D., president and chief executive officer, will participate in a fireside chat at the...
Mar 18, 2021 08:00 am ET
Generation Bio Reports Fourth Quarter and Full Year 2020 Financial Results
Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, reported recent business highlights and fourth quarter and full year 2020 financial results. “2020 was a foundational year...
Feb 18, 2021 07:30 am ET
Generation Bio Appoints Ron Cooper to Its Board of Directors
Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of gene therapy, announced today that Ron Cooper has been appointed to its Board of Directors. The appointment is effective March 1, 2021. Ron Cooper...
Jan 11, 2021 05:43 pm ET
Generation Bio Announces Closing of Public Offering
Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of gene therapy, today announced the closing of its public offering of 9,200,000 shares of its common stock at a public offering price of $24.50 per...
Jan 06, 2021 09:23 pm ET
Generation Bio Announces Pricing of Public Offering
Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of gene therapy, today announced the pricing of a public offering of 8,000,000 shares of its common stock at a public offering price of $24.50 per...
Jan 05, 2021 06:30 am ET
Generation Bio to Present at 39th Annual J.P. Morgan Healthcare Conference
Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, announced today that the company will present at the virtual 39th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan....
Jan 04, 2021 06:30 am ET
Generation Bio Announces Two Non-Viral Gene Therapy Milestone Achievements: Target Levels of Factor VIII Expression in Hemophilia A Mice and Translation of Expression from Mice to Non-Human Primates
Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, announced data today from a study achieving tolerability and targeted factor VIII expression levels in hemophilia A mice...
Nov 10, 2020 06:30 am ET
Generation Bio Reports Third Quarter 2020 Business Updates and Financial Results
Generation Bio Co. (Nasdaq: GBIO) is an innovative genetic medicines company creating a new class of non-viral gene therapy. Today the company reported recent business highlights and third quarter financial results. “2020 continues to be a year...
Oct 05, 2020 06:30 am ET
Generation Bio to Present at 2020 Virtual Cell & Gene Meeting on the Mesa
Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, announced today that Phillip Samayoa, vice president of strategy and portfolio development, will present a company overview...
Sep 24, 2020 06:30 am ET
Generation Bio to Present at the Jefferies 2020 Virtual Gene Therapy/Editing Summit
Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, announced today that Geoff McDonough, M.D., president and chief executive officer, will present at the Jefferies 2020 Virtual...
Aug 11, 2020 06:30 am ET
Generation Bio Reports Business Updates and Second Quarter 2020 Financial Results
Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, today reported recent business highlights and second quarter financial results. “The first half of 2020 has seen...
Aug 05, 2020 06:30 am ET
Generation Bio to Present at 2020 Wedbush PacGrow Healthcare Virtual Conference
Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, today announced that management will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference on Wednesday, Aug. 12,...
Jul 22, 2020 07:00 am ET
Generation Bio Appoints Matthew Norkunas, M.D., MBA as Chief Financial Officer
Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, today announced that Matthew Norkunas, M.D., MBA, has been appointed chief financial officer. “We are delighted to add...
Jun 16, 2020 04:02 pm ET
Generation Bio Announces Closing of Initial Public Offering
Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of gene therapy, today announced the closing of its initial public offering of 12,105,263 shares of its common stock at an initial public offering price...
Jun 11, 2020 09:52 pm ET
Generation Bio Announces Pricing of Initial Public Offering
Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of gene therapy, today announced the pricing of its initial public offering of 10,526,316 shares of its common stock at an initial public offering price...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.